Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelimumab plus AG chemotherapy as first-line treatment for advanced pancreatic cancer
ChiCTR2300077358Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in pancreatic adenocarcinoma (PDAC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: progression-free survival. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2300077358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077358.